



MEDICAL TIPS

DIABIZ TABLETS

Issue I, No. 1, 2022

Dapagliflozin does not increase risk of severe UTIs or acute liver injury

Johannes C et.al, 81st Annual Scientific Sessions of the American Diabetes Association: abstr. 805-P, 25 Jun 2021

- Real-world post-authorisation studies collated the data from 03 different cohorts from USA & UK countries between 2012-19 periods.
- The objective was to investigate, the risk of severe UTIs & hospitalized acute liver injury amongst T2DM patients on Dapagliflozin & compared them with patients on other anti-hyperglycemic agents like Metformin, Sulphonylureas & Insulin.
- Pooled data showed that dapagliflozin did not significantly increase the incidence of severe complications of UTIs in women or in men.
- The number of patients hospitalised with dapagliflozin-related acute liver injury was low in all cohorts, and the pooled rate was not significant.

Dapagliflozin does not appear to increase the risk of severe complications of urinary tract infections (UTIs) or hospitalization for acute liver injury compared with other anti-hyperglycaemics.

